PT - JOURNAL ARTICLE AU - Ayhan, Ali AU - Yilmaz Baran, Safak AU - Vatansever, Dogan AU - Dogan Durdag, Gulsen AU - Akilli, Huseyin AU - Celik, Husnu AU - Taskiran, Cagatay TI - Feasibility of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer during COVID-19 pandemic AID - 10.1136/ijgc-2021-002511 DP - 2021 Jun 01 TA - International Journal of Gynecologic Cancer PG - 883--887 VI - 31 IP - 6 4099 - http://ijgc.bmj.com/content/31/6/883.short 4100 - http://ijgc.bmj.com/content/31/6/883.full SO - Int J Gynecol Cancer2021 Jun 01; 31 AB - Objective This study aims to evaluate the effect of the COVID-19 pandemic and related restrictions on patients who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer.Methods We retrospectively evaluated ovarian cancer patients who underwent HIPEC following complete cytoreductive surgery performed during the outbreak of the COVID-19 pandemic in three different centers specializing in gynecological oncology. All patients who underwent cytoreduction plus HIPEC for a primary, interval, and recurrent surgery were evaluated. Primary outcomes was postoperative 30-day morbidity and mortality. The secondary outcome was infection of patient and/or related staff with COVID-19 during the perioperative or early postoperative period.Results We performed a total of 35 HIPEC procedures during the pandemic: 15 (42.9%) patients underwent primary/interval surgery, while 20 (57.1%) patients had recurrent disease. Grade 3–4 complications occurred in one patient (2.9%) (chronic renal failure), while mortality did not occur in any patient. Neither the patients nor related staff were infected with the coronavirus during the perioperative or early postoperative period. One patient, who was diagnosed with COVID-19 pneumonia on postoperative day 80 died from the infection. Another patient died on postoperative day 85 due to progressive ovarian cancer, a disorder in vital functions, and organ failure.Conclusion HIPEC during the COVID-19 pandemic seems a safe and feasible procedure, with acceptable morbidity and mortality rates. Careful selection of patients is important and precautions should be taken before the procedure.Data are available upon reasonable request. The data that support the findings of this study are available from the corresponding author, SYB, upon reasonable request.